Two Nasdaq Companies Got Second Bid-Price Windows Running to March 1, 2027. A Third Closed Its Case Today

by Wesley Stroud · September 4, 2026

Micro-Cap Markets Correspondent, The MicroCap Herald

Three Nasdaq bid-price disclosures landed between Tuesday and today, and read together they show the two ways a $1.00 shortfall ends: a company gets more time, or it gets the price back.

CLPS Incorporation said in a release dated Sept. 4 that it has regained compliance with Nasdaq Listing Rule 5450(a)(1). "The minimum bid price of the Company's common share was $1.00 per share or greater for the last 10 consecutive trading days from August 20 through September 2, 2026," the release states, adding that CLPS "has regained full compliance with Nasdaq's Listing Rule 5450(a)(1), and the matter is now closed." The announcement does not say whether the recovery followed a corporate action or ordinary trading.

The rule CLPS cites carries a different number from the one the other two companies cite. Alpha Compute Corp. and DeFi Technologies both reference Listing Rule 5550(a)(2), the bid-price provision applicable to their Nasdaq Capital Market listings. The ten-day mechanic is the same in each case: a closing bid price at or above $1.00 for ten consecutive trading days ends the deficiency.

Alpha Compute Corp., which describes itself as "a vertically integrated AI infrastructure company specializing in GPU-as-a-service and AI Confidential Compute" and trades on the Nasdaq Capital Market under ALP, said in a Sept. 1 release that Nasdaq notified it by letter dated Aug. 31 that it had been granted an additional 180-calendar-day period, until March 1, 2027, to regain compliance. Its original deficiency notice was dated March 2, 2026.

The release sets out what the company had to do to get the second window. "The Company also provided written notice to Nasdaq of its intention to cure the deficiency during the second compliance period, including, if necessary, by effecting a reverse share split," Alpha Compute said. Chief executive Brittany Kaiser said in the release that the company intends "to use every tool available to us, including a reverse share split if required, to protect our listing and our shareholders."

DeFi Technologies Inc., which trades on the Nasdaq Capital Market under DEFT, disclosed a nearly identical outcome on Sept. 3. Its original deficiency notice was dated March 5, 2026, and its additional compliance period also runs to March 1, 2027. "The Company has provided written notice of its intention to cure the deficiency during the second compliance period," the release says. Management said it will continue monitoring the closing bid price and evaluate available options during the second period. The DeFi Technologies release does not name a reverse split as a contemplated remedy.

The coincidence of dates is worth noting for anyone tracking these clocks. The two original notices were three days apart in early March, yet both second periods expire on the same day, March 1, 2027. Neither release sets out how the date was calculated, and this desk did not obtain the underlying Nasdaq letters, so the reason is not established here.

What the two releases do establish is the structure of the second window. It is not automatic in the sense of arriving unrequested: on the Capital Market a company must meet the other applicable initial listing standards and tell Nasdaq in writing that it intends to cure the shortfall, including by a reverse split if that becomes necessary. Alpha Compute's release describes exactly that sequence. An additional period is therefore best read as a conditional extension rather than a resolution.

It also comes with the exchange's standard caveat, which DeFi Technologies reproduced: "There can be no assurance that the Company will regain compliance within the additional compliance period or otherwise maintain compliance with Nasdaq's continued listing requirements."

A separate disclosure this week is a useful contrast because it involves a different clock entirely. Anavex Life Sciences said on Sept. 2 that Nasdaq confirmed it is again in compliance with Listing Rule 5250(c)(1), the periodic filing requirement, after it filed its outstanding Form 10-Q reports for the second and third fiscal quarters of 2026 on Aug. 28. "The Company is now in compliance with all Nasdaq listing standards," that release says. Anavex trades on the Nasdaq Global Select Market. A filing deficiency is cured by filing; a price deficiency is not.

For readers holding or following any of these names, the practical distinctions matter. A second 180-day period preserves a listing while the price problem remains unsolved, and the most common tool for solving it in this part of the market is a reverse split. A reverse split raises a quoted price arithmetically without adding capital, and it does not by itself change the amount of stock a company may go on to issue.

Regaining compliance, as CLPS reported today, closes the specific matter but does not exempt a company from the rule going forward: a renewed sustained fall below $1.00 can start the process again.

None of the three companies is described here as being at imminent risk of removal from the exchange, and none of the releases reviewed for this article announces a delisting determination. The risks that do sit plainly on the record are that two of the three still have a bid price below the exchange's threshold, that both have told Nasdaq they intend to cure it during a period that runs into next year, and that one of them has named a reverse split as a tool it is prepared to use.

US markets were open as this article was written, at roughly 11:20 a.m. Eastern on Friday, and no price for today's session is reported here. Monday, Sept. 7, is Labor Day, so the next regular session is Tuesday, Sept. 8.

This article summarises company disclosures and exchange rule mechanics. It is not investment advice, and The MicroCap Herald expresses no view on any of the securities mentioned.